AZNAstraZenecaSigning up patients
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 420 (planned)
- Started
- May 5, 2026
- Main results expected
- Aug 29, 2031
- Fully finished
- Apr 5, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
DOSRI- Number of participants with adverse events (AEs) and Serious Adverse Events (SAEs)
Measured over: Up to 5 years
Phase III- Progression Free Survival (PFS)
Measured over: Until disease progression or death (up to 5 years)
DOSRI- Number of participants with study intervention discontinuations, dose reductions and dose delays due to AEs
Measured over: Up to 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07509151 · record last updated 2026-10-06 · checked 2026-11-09 15:47 UTC